market analyst, marketanalyst.net, market analyst llc, market research & analyst



Payment Options


  Home > Markets & Markets >

Neuromodulation Market [Spinal Cord Stimulation(SCS), Vagus Nerve Stimulation(VNS), Gastric Electrical Stimulation(GES), Deep Brain Stimulation(DBS), Sacral Nerve Stimulation(SNS), & Transcranial Magnetic Stimulation(TMS)] - Forecasts to 2017
Neuromodulation Market [Spinal Cord Stimulation(SCS),   Vagus Nerve Stimulation(VNS),   Gastric Electrical Stimulation(GES),   Deep Brain Stimulation(DBS),   Sacral Nerve Stimulation(SNS),  & Transcranial Magnetic Stimulation(TMS)] - Forecasts to 2017


 


Price:
$4,650.00

Publisher: Markets & Markets
Publication: Date: 193
No. of Pages: 16-Jan-13
Delivery Format: PDF

Product Code: MM-130118



License types*:


 
Description Contents
 
Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non-invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS).

The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder.

The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S.

This report estimates the market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation.

The key players in the neuromodulation devices market are Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), Enteromedics, Inc (U.S.), Neuropace, Inc (U.S.), Zynex, Inc (U.S.) and Neuronetics, Inc (U.S.). The emerging players in this market are Functional Neuromodulation, Ltd (U.S.), Microtransponder (U.S.), and Neurosigma, Inc (U.S.).

Scope of the Report

The research report categorizes the global neuromodulation devices market by procedure, technology, and application. These markets are broken down into segments and sub-segments, providing exhaustive value-volume analysis for 2010, 2011, and 2012 as well as forecast up to 2017. Each market is also analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World to provide in-depth information on the global scenario.

Global Neurostimulation Devices Market, by Procedure:

Internal Neurostimulation
Spinal Cord Stimulation (SCS)
Failed Back Surgery Syndrome
Chronic Pain
Ischemic Pain
Others
Deep Brain Stimulation (DBS)
Movement Disorders
Parkinson's  Disease
Alzheimer's Disease
Dystonia
Tourette's Syndrome
Others
Chronic Pain
Depression
Post-Traumatic Coma
Sacral Nerve Stimulation (SNS)
Urine Incontinence
Fecal Incontinence
Vagus Nerve Stimulation (VNS)
Epilepsy disease
Heart Failure
Tinnitus
Others
Gastric Electrical Stimulation (GES)
Gastroparesis
Others
External Neurostimulation  
Transcranial Magnetic Stimulation (TMS)
Depression
Tinnitus
Migraine
Stroke
Others
Transcutaneous Electrical Nerve Stimulation (TENS)
Global Neurostimulation Devices Market, by Geography

North America
Europe
Asia-Pacific
Rest of the World


Browse for more products in the same category as this item:

Markets & Markets
Regions > Global
Industry > Healthcare & Pharmaceuticals > Medical Devices & Equipment > Medical Devices Industry